• There’s still value in biotech stocks: Citi pro Monday, 7 Apr 2014 | 6:23 PM ET

    Despite the recent meltdown in biotech, there are still areas of opportunity within the sector, Citi's Yaron Werber says.

  • Diversifying your pharma portfolio     Monday, 7 Apr 2014 | 1:07 PM ET

    Mallinckrodt is buying drug maker Questcor for $5.6 billion. Barbara Ryan, FTI Consulting managing director, discusses consolidation in pharmaceuticals and shares what stocks she likes in the space.

  • CNBC's Seema Mody and Dominic Chu look at what's behind today's massive market sell off including biotechs and online retailers.

  • Heather Bresch Mylan CEO, discusses the concern over capping drug prices and the impact of Obamacare on rising drug costs.

  • Why investors should be exposed to biotech     Monday, 31 Mar 2014 | 5:30 AM ET

    Jason Kolbert, head of health care research at Maxim Group, says that last week's biotech sell-off was not justified as the sector is going through a "paradigm shift" which should results in higher valuations.

  • Max Herrmann, partner and healthcare research analyst at Oriel Securities, said biotech stocks have gone through a correction after a "phenomenal" rally.

  • Why drug treatment prices vary     Wednesday, 26 Mar 2014 | 1:08 PM ET

    The U.S. government is prohibited by law from negotiating drug prices, reports CNBC's Sheila Dharmarajan.

  • Reasons to stick with biotech     Tuesday, 25 Mar 2014 | 3:37 PM ET

    CNBC's Sheila Dharmarajan discusses the beat down biotech stocks have recently taken and gives 3 reasons why investors should stick with the sector.

  • Reasons to stick with biotech     Tuesday, 25 Mar 2014 | 1:07 PM ET

    CNBC's Sheila Dharmarajan reports why analysts think investors should stick with the biotech sector.

  • Gilead's next move     Tuesday, 25 Mar 2014 | 12:13 PM ET

    Gilead received a letter from U.S. lawmakers questioning the pricing of its hepatitis c drug Solvadi. Mark Schoenebaum, ISI Health Care Research Group senior managing director, provides perspective.

  • Cramer: Need to see IPO competition cease     Tuesday, 25 Mar 2014 | 9:01 AM ET

    CNBC's Jim Cramer shares his thoughts on yesterday's Nasdaq selloff and the slumping biotech sector.

  • Biotech could see more weakness: Pro     Monday, 24 Mar 2014 | 2:03 PM ET

    Barbara Ryan, FTI Consulting, and Matt Maley, MillerTabek and Company, discuss what has propelled the massive sell-off in the biotech sector.

  • Biotech's big drop     Monday, 24 Mar 2014 | 1:01 PM ET

    CNBC's Dominic Chu digs into the battered biotech sector and reveals which stocks are still sliding.

  • Warning signs in the market     Monday, 24 Mar 2014 | 12:00 PM ET

    The FMHR traders discuss what warning signs bull investors should be looking for in the stock market and concerns about a biotech bubble.

  • What's working in biotech: CELG, ALXN & more     Monday, 24 Mar 2014 | 8:05 AM ET

    U.S. lawmakers sent a letter to Gilead requesting information on pricing for its hepatitis c drug Sovaldi. Christopher Raymond of R.W. Baird.

  • Analyst likes large cap biotechs     Friday, 21 Mar 2014 | 2:06 PM ET

    Discussing the market's big reaction to news U.S. lawmakers requested information about Gilead's hepatitis C drug Sovaldi, and which stocks are attractive in the sector, with Geoff Porges, Bernstein Research senior analyst.

  • Biotech weighs on S&P     Friday, 21 Mar 2014 | 1:02 PM ET

    CNBC's Dominic Chu reports the health care sector is being dragged down by the biotech sector. Congressional Democrats asked biotech company Gilead to provide insight on pricing for its hepatitis C drug Sovaldi.

  • US Democrats ask Gilead about pricing     Friday, 21 Mar 2014 | 12:30 PM ET

    CNBC's Sheila Dharmarajan reports on the decline in the Nasdaq because of the hit to the biotechs. Gilead received a letter from senior Democrats requesting a briefing on the pricing for its hepatitis C drug Sovaldi.

  • MediWound makes US market debut     Thursday, 20 Mar 2014 | 10:48 AM ET

    MediWound develops treatments for severe burns and hard to heal wounds. Gal Cohen, MediWound CEO, discusses his company's medical solutions and the results of its IPO.

  • Pisani: Momentum names holding up     Friday, 14 Mar 2014 | 3:42 PM ET

    CNBC's Bob Pisani discusses the IPO of Castlight Health and how classic momentum stocks are trading, and CNBC's Sheila Dharmajan looks at what biotech stocks are getting hit hard.